title: Emerging role of PPAR-β/δ in inflammatory process associated to experimental periodontitis.
abstract: The aim of the present study was to evaluate the contribution of peroxisome proliferator-activated receptor (PPAR-β/δ) in animal model of periodontitis. Male Sprague-Dawley rats were lightly anaesthetized with pentobarbitone (35 mg/kg). Sterile, 2-0 black braided silk thread was placed around the cervix of the lower left first molar and knotted medially. Animals received GW0742 (0.3 mg/kg, 10% DMSO, i.p. after the ligature placement and daily for eight days). At day 8, the gingivomucosal tissue encircling the mandibular first molar was removed. One the eighth day after placement of the ligature, we evaluated (1) NF-κB expression, (2) cytokines expression, (3) iNOS expression, (5) the nitration of tyrosine, (6) apoptosis, and (8) the degree of gingivomucosal tissues injury. Administration of GW0742 significantly decreased all of the parameters of inflammation as described above. Taken together, these results demonstrate that GW0742 exerts an anti-inflammatory role during experimental periodontitis and is able to ameliorate the tissue damage.
authors: IRCCS Centro Neurolesi Bonino-Pulejo, 98125 Messina, Italy.
authors: Rosanna
authors: R
authors: Di Paola
authors: Francesco
authors: F
authors: Briguglio
authors: Irene
authors: I
authors: Paterniti
authors: Emanuela
authors: E
authors: Mazzon
authors: Giacomo
authors: G
authors: Oteri
authors: David
authors: D
authors: Militi
authors: Giancarlo
authors: G
authors: Cordasco
authors: Salvatore
authors: S
authors: Cuzzocrea
mesh_terms: D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology*; D001862:Bone Resorption / Q000517:prevention & control; D002199:Capillary Permeability / Q000187:drug effects; D016207:Cytokines / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D008297:Male; D016328:NF-kappa B / Q000378:metabolism; D020556:Neutrophil Infiltration / Q000187:drug effects; D052247:Nitric Oxide Synthase Type II / Q000032:analysis; D047494:PPAR delta / Q000819:agonists / Q000502:physiology*; D048068:PPAR-beta / Q000819:agonists / Q000502:physiology*; D010518:Periodontitis / Q000188:drug therapy* / Q000209:etiology; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000032:analysis; D051381:Rats; D017207:Rats, Sprague-Dawley; D013844:Thiazoles / Q000494:pharmacology* / Q000627:therapeutic use; D014443:Tyrosine / Q000031:analogs & derivatives / Q000378:metabolism; D051028:bcl-2-Associated X Protein / Q000032:analysis; D010636:Phenols; D013438:Sulfhydryl Compounds
chemical_list: D000893:Anti-Inflammatory Agents; D016207:Cytokines; D016328:NF-kappa B; D052247:Nitric Oxide Synthase Type II; D047494:PPAR delta; D048068:PPAR-beta; D019253:Proto-Oncogene Proteins c-bcl-2; D013844:Thiazoles; D014443:Tyrosine; D051028:bcl-2-Associated X Protein; C494828:Bax protein, rat; C002744:3-nitrotyrosine; C479979:(4-(((2-(3-fluoro-4-(trifluoromethyl)phenyl)-4-methyl-1,3-thiazol-5-yl)methyl)sulfanyl)-2-methylphenoxy)acetic acid; D010636:Phenols; D013438:Sulfhydryl Compounds